8月7日，Moderna盘中上涨5.31%，报56.72美元/股，成交额6947.96万美元。
消息面上，公司宣布其季节性流感疫苗mFLUSIVA正式获得美国FDA批准，获批用于50岁及以上成人，成为公司在美国获批的第四款产品，也是全球首款进入流感市场的mRNA疫苗。公司预计该疫苗将在未来数周内于部分零售渠道供应，覆盖2026-2027呼吸道病毒季。此外，该疫苗目前正在澳大利亚、加拿大和欧洲接受监管审查。
此前公司流感疫苗候选产品曾获FDA咨询委员会9票赞成、0票反对的一致支持，多家机构亦同步上调目标价：瑞银上调至50美元，高盛上调至67美元，杰富瑞上调至60美元，为获批后股价表现提供催化。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.